¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"pressure flow study"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
¿µ¹® cohort study ÇÑ±Û °èȹ¿¬±¸, ÀüÇ⿬±¸, ¾Õ¹æÇ⿬±¸
¼³¸í   
  ºÐ¼®¿ªÇп¡¼­ÀÇ ¿äÀÎ-´ëÁ¶¿¬±¸ÀÇ ÇÑ ±â¹ýÀÌ´Ù. »ç¶÷ÀÇ Áý´Ü¿¡¼­ Áúº´À¯Çà°ú °¡¼³¿äÀΰúÀÇ ¿¬°ü¼ºÀ» °íÂûÇÏ¿© Àΰú°ü°è¸¦ ¹àÈ÷´Â °ÍÀ» ¸ñÀûÀ¸·Î ÇÑ´Ù. °¡¼³¿äÀÎÀ» °®´Â Áý´Ü°ú °®Áö ¾Ê´Â Áý´Ü, È¤Àº ÀûÀº Áý´Ü°ú ¸¹Àº Áý´ÜÀÇ 2±º(ÄÚȣƮ)À¸·Î ³ª´©¾î ÃßÀû Á¶»çÇÏ¿© °¢ Áý´Ü¿¡¼­ÀÇ Áúº´ÀÇ ¹ß»ýºóµµ¸¦ ºñ±³Çϴ °ÍÀÌ´Ù. ÀϹÝÀûÀ¸·Î´Â ÀüÇâÀûÀΠ¿¬±¸·Î ÇàÇØÁö´Â °æ¿ì°¡ ¸¹À¸³ª ÈÄÇâÀûÀΠ¿¬±¸·Îµµ ÇàÇÏ¿©Áø´Ù.
¿µ¹® flow ÇÑ±Û È帧, À¯·®
¼³¸í   
  ¾×ü ¶Ç´Â ±âüÀÇ °¢ ºÎºÐÀÌ ½Ã°£°ú ÇÔ²² ¿¬¼ÓÀûÀ¸·Î ±× À§Ä¡¸¦ À̵¿Çϴ Çö»ó. ±× ¾ç»óÀº º¹ÀâÇÏÁö¸¸ °¢ Á¡¿¡¼­ÀÇ È帧ÀÇ ¹æÇâÀÌ ±× Á¡¿¡¼­ÀÇ Á¢¼± ¹æÇâ°ú ÀÏÄ¡Çϵµ·Ï ¼±À» ±×À¸¸é È帧ÀÇ ¸ð¾çÀ» ÆÄ¾ÇÇÒ ¼ö ÀÖ°Ô µÈ´Ù.
¿µ¹® intermittent positive pressure breathing(IPPB) ÇÑ±Û °£ÇæÀû¾ç¾ÐÈ£Èí
¼³¸í   
  Æó¸¦ ÆØÃ¢½Ã۱â À§ÇÏ¿© ´ë±â¾Ðº¸´Ù ³ôÀº ¾Ð·ÂÀ» ÀÌ¿ëÇϴ ÀΰøÈ£Èí¹ýÀÌ´Ù. ½Å»ý¾Æ ¹«±âÆóÀÇ Ä¡·á³ª ¸¸¼º Æó¼â¼º È£Èí±â ÁúȯÀÇ ±Þ¼º ¾ÇÈ­½Ã, Áø´ÜÀ» À§ÇÑ °¡·¡ÀÇ ¹èÃâÀ» À§ÇÏ¿©, ¶Ç´Â ¾àÁ¦ÀÇ ÈíÀÔ¿¡ »ç¿ëÇϰí ÀÖ´Ù. ÇÕº´ÁõÀ¸·Î °ø±â°¡½¿ÁõÀ̳ª ½É¹ÚÃâ·®ÀÇ °¨¼Ò°¡ ¿Ã ¼ö ÀÖ´Ù.
¿µ¹® pulse pressure ÇÑ±Û ¸Æ¹Ú¾Ð
¼³¸í   
  ¼öÃà±â Ç÷¾Ð°ú È®Àå±â Ç÷¾ÐÀÇ Â÷ÀÌ. mmHg·Î Ç¥½ÃÇÑ´Ù. ½ÉÀåÀÇ ¼öÃà·Â, µ¿¸Æ ³» Ç÷·ù·®, µ¿¸Æº®ÀÇ ±äÀåµµ¿¡ ¿µÇâÀ» ¹Þ´Â´Ù. Á¤»óÄ¡´Â ¼öÃà±â Ç÷¾ÐÀÇ 1/3, ¶Ç´Â È®Àå±â Ç÷¾ÐÀÇ 1/2ÀÌ´Ù. 60mmHgÀÌ»óÀ» ´ë¸ÆÀ̶ó°í Çϸç, ´ëµ¿¸ÆÆÇ¸· Æó¼âºÎÁ·Áõ, °©»ó»ùÇ×ÁøÁõ, µ¿¸Æ°æÈ­Áõ, Ç÷¾ÐÀÌ »ó½ÂÇÒ ¶§ ½ÉÀåºñ´ë, °í¿­ µî¿¡¼­ º¼ ¼ö ÀÖ´Ù. 20mmHg ÀÌÇϸ¦ ¼Ò¸ÆÀ̶ó°í Çϸç, ±Þ¼º ½É±Ù°æ»ö¿¡ ÀÇÇÑ Á½ɽǠ¼öÃà·Â ÀúÇÏ, ´ëµ¿¸ÆÆÇ¸· ÇùÂøµî¿¡¼­ º¼ ¼ö ÀÖ´Ù. ÇÑÆí ¸Æ¾ÐÀÇ 1/3¿¡ È®Àå±â Ç÷¾ÐÀ» ´õÇÑ °ÍÀ» Æò±ÕÇ÷¾ÐÀ̶ó°í ÇÑ´Ù.
  
  
¿µ¹® osmotic pressure ÇÑ±Û »ïÅõ¾Ð
¼³¸í   
  »ïÅõ¶ó´Â Çö»óÀº ÀÏÁ¤ Å©±â ÀÌÇÏÀÇ ¹°ÁúÀº Åë°ú½ÃŰ°í ±× ÀÌ»óÀÇ Å©±â¸¦ °¡Áø ¹°ÁúÀº Åë°ú ½ÃŰÁö ¸øÇϰԠÇϴ ¸·(¹ÝÅõ¸·)À» »çÀÌ¿¡ µÎ°í ¾çÂÊ¿¡ ±× ¸·À» Åõ°úÇÏÁö ¸øÇϴ ¹°ÁúÀÇ ³óµµ°¡ Â÷À̰¡ ³¯ ¶§ ¹ß»ýÇϴ °ÍÀ¸·Î ¸·À» Åë°úÇÒ ¼ö Àִ ¹°ÁúÀÌ ¸· ¾çÂÊÀÇ Åë°ú ÇÒ ¼ö ¾ø´Â ¹°ÁúÀÇ ³óµµ¸¦ °°°Ô Çϴ ¹æÇâÀ¸·Î ¿òÁ÷À̴ °ÍÀ» ¸»ÇÑ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • pressure flow study
    ¾Ð·Â¿ä·ù°Ë»ç
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • air study
    °ø±âÁÖÀÔ°Ë»ç
  • cohort study
    ÄÚȣƮ¿¬±¸, ÄÚȣƮÁ¶»ç
  • controlled clinical study
    °ü¸®È­ÀÓ»ó½ÃÇè
  • crossover study
    ±³Â÷¿¬±¸
  • cross-sectional study
    ´Ü¸é¿¬±¸
  • case comparison study
    ȯÀÚ´ëÁ¶±º¿¬±¸
  • case referent study
    ȯÀÚ´ëÁ¶±º¿¬±¸
  • case study
    Áõ·Ê¿¬±¸, »ç·ÊÁ¶»ç
  • case-control study
    ȯÀÚ´ëÁ¶±º¿¬±¸, »ç·Ê´ëÁ¶±º¿¬±¸
  • diachronic study
    ºñµ¿½Ã¿¬±¸
  • double blind study
    ÀÌÁ߸Ͱ˿¬±¸
  • ecological study
    »ýÅ¿¬±¸
  • feasibility study
    °¡´É¼º¿¬±¸
  • follow-up study
    ÃßÀûÁ¶»ç
  • family study
    °¡Á·Á¶»ç
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • flow cytometry
    È帧¼¼Æ÷ÃøÁ¤
  • flow
    1.È帧, 2.À¯·®
  • blood flow
    Ç÷·ù
  • blood flow rate
    Ç÷·ù·®, Ç÷·ù¼Óµµ
  • peak expiratory flow rate
    ÃÖ°í³¯¼û¼Óµµ, ÃÖ°íÈ£±âÀ¯¼Ó
  • blood flow velocity
    ÇÇÈ帧¼Óµµ, Ç÷·ù¼Óµµ
  • study design
    ¿¬±¸¼³°è
  • study
    ¿¬±¸, °Ë»ç, Á¶»ç
  • arterial blood gas study
    µ¿¸ÆÇ÷°¡½ººÐ¼®
  • case-control study
    ȯÀÚ´ëÁ¶±º¿¬±¸
  • cohort study
    ÄÚȣƮ¿¬±¸
  • cross-sectional study
    ´Ü¸éÁ¶»ç¿¬±¸
  • ecological study
    »ýÅ¿¬±¸
  • longitudinal study
    ÃßÀû¿¬±¸
  • observational study
    °üÂû¿¬±¸
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • pressure flow study
    ¾Ð·Â¿ä·ù°Ë»ç
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • pressure-perfusion study
    ¾Ð·Â°ü·ù°Ë»ç
  • air study
    °ø±âÁÖÀÔ°Ë»ç
  • arterial blood gas study
    µ¿¸ÆÇ÷°¡½ººÐ¼®
  • cardiac gated MR study
    ½ÉÀ嵿±âÀÚ±â°ø¸í°Ë»ç
  • case study
    Áõ·Ê¿¬±¸
  • case comparison study
    ȯÀÚ´ëÁ¶±º¿¬±¸
  • case compeer study
    ȯÀÚ´ëÁ¶±º¿¬±¸
  • case referent study
    ȯÀÚ´ëÁ¶±º¿¬±¸
  • case-base study
    ȯÀÚ¸ðÁý´Ü¿¬±¸
  • case-control study
    (¢¡retrospective) ÈÄÇ⿬±¸, µÞ¹æÇ⿬±¸
  • cohort study
    (¢¡prospective) °èȹ¿¬±¸, ÀüÇ⿬±¸, ¾Õ¹æÇ⿬±¸
  • controlled clinical study
    °ü¸®È­ÀÓ»ó½ÃÇè
  • cross-sectional study
    ´Ü¸éÁ¶»ç¿¬±¸
  • double-blind study
    ÀÌÁ߸Ͱ˹ý
  • study design
    ¿¬±¸°èȹ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • pressure flow study
    ¾Ð·ù·® Á¶»ç
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • pressure-perfusion study
    ¾Ð·Â°ü·ù°Ë»ç
  • B cell study
    B ¼¼Æ÷°Ë»ç
  • air study
    °ø±â(ÁÖÀÔ) °Ë»ç(¹ý)
  • arterial blood gas study
    µ¿¸ÆÇ÷ °¡½ººÐ¼®
  • infection control study
    °¨¿°°ü¸®¿¬±¸
  • phase 1 study
    ÀÓ»óÁ¦1»ó½ÃÇè.
  • pilot study
    ¿¹ºñ½ÇÇè.
  • population study
    Àα¸Á¶»ç
  • preclinical study
    ÀüÀÓ»ó½ÃÇè(îñìúßÉãËúÐ).
  • prospective study
    °èȹÀû¿¬±¸, ÀüÇâÀû¿¬±¸
  • real time study
    ½Ç½Ã°£ °Ë»ç
  • hepatic venous wedge pressure =wedged h.vein pressure
    Æó»ö°£Á¤¸Æ¾Ð( øÍßáÊÜð¡Øæäâ).
  • ELBF=£¾effective liver blood flow
    À¯È¿¼º °£Ç÷·ù.
  • ELBF=£¾effective liver blood flow
    À¯È¿ °£Ç÷·ù.
  • ERPF => effective renal plasma flow
    À¯È¿½ÅÇ÷ÀåÀ¯Åë·®
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • pressure flow study
    ¾Ð·ù·® Á¶»ç
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • pressure-perfusion study
    ¾Ð·Â°ü·ù°Ë»ç
  • hepatic venous wedge pressure =wedged h.vein pressure
    Æó»ö°£Á¤¸Æ¾Ð( øÍßáÊÜð¡Øæäâ).
  • air study
    °ø±â(ÁÖÀÔ) °Ë»ç(¹ý)
  • arterial blood gas study
    µ¿¸ÆÇ÷ °¡½ººÐ¼®
  • cardiac gated MR study
    ½ÉÀ嵿±â ÀÚ±â°ø¸í °Ë»ç
  • case control study
    ȯÀÚ´ëÁ¶¿¬±¸.
  • case study
    Áõ·Ê¿¬±¸(Áõ¿¹¿¬±¸).
  • case study
    Áõ·Ê¿¬±¸(ñøçÓæÚϼ).
  • cohort study
    ÄÚ¿ÀÆ®¿¬±¸(ÊÙËçË´), Æø·ÎºñÆø·Î¿¬±¸.
  • controlled clinical study
    (Ãß°èÇÐÀû) °ü¸®È­(Ì§Ë­Ì°ËøË´ËöÌ´)(ÀÓ»ó)½ÃÇè( ËöË×ËàÌ´).
  • double-blind study
    ÀÌÁ߸ͰË.
  • family study
    °¡Á·Á¶»ç(¿¬±¸)
  • first pass study
    ÀÏÂ÷Åë°ú°Ë»ç.
  • follow-up study
    ÃßÀûÁ¶»ç
  • infection control study
    °¨¿°°ü¸®¿¬±¸
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • blance study
    ±ÕÇü¿¬±¸(гû¬æÚϼ)
  • colloid osmotic pressure
    ÄÝ·ÎÀÌµå »ïÅõ¾Ð(ß¶÷âäâ)
  • critical pressure
    ÀÓ°è¾Ð(×üÍ£äâ)
  • electron pressure
    ÀüÀÚ¾Ð(ï³í­äâ)
  • high-pressure liquid chromatography
    °í¾Ð(ÍÔäâ) ¾×ü(äûô÷)Å©·Î¸¶Åä±×·¡ÇÇ
  • oncotic pressure
    ±³Áú»ïÅõ¾Ð(Îéòõß¶÷âäâ)
  • osmotic pressure
    »ïÅõ¾Ð(ß¶÷âäâ)
  • partial pressure
    ºÐ¾Ð(ÝÂäâ)
  • pressure dialysis
    °¡¾ÐÅõ¼®(Ê¥äâ÷âà°)
  • pressure-jump method
    ¾Ð·Â(äâÕô)-¶Ù±â¹ý(Ûö)
  • reduced osmotic pressure
    ȯ»ê »ïÅõ¾Ð(üµß©ß¶÷âäâ)
  • standard pressure
    Ç¥ÁØ ¾Ð·Â(øöñÞäâÕô)
  • surface pressure
    Ç¥¸é¾Ð (øúØüäâ)
  • total osmotic pressure
    ÃÑ»ïÅõ¾Ð (õÅß¶÷âäâ)
  • vapor pressure osmometer
    Áõ±â¾Ð(ñúѨäâ) »ïÅõ°è(ß¶÷âͪ)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • air study
    °ø±â(ÁÖÀÔ)°Ë»ç(¹ý)
  • cardiac gated MR study
    ½ÉÀ嵿±âÀÚ±â°ø¸í°Ë»ç
  • pilot study
    ¿¹ºñ½ÇÇè
  • prospective study
    ÀüÇâÀû¿¬±¸
  • real time study
    ½Ç½Ã°£°Ë»ç
  • retrospective study
    ÈÄÇ⼺¿¬±¸
  • study of choice
    ÃÖ¼±ÀÇ °Ë»ç
  • central venous pressure
    Áß½ÉÁ¤¸Æ¾Ð
  • increased intracranial pressure
    µÎ°³³»¾ÐÇ×Áø
  • intermittent positive pressure ventilation
    °£ÇæÀû¾ç¾Ðȯ±â¹ý
  • maximal blood pressure
    ÃÖ´ëÇ÷¾Ð, ÃÖ°íÇ÷¾Ð
  • osmotic pressure
    »ïÅõ¾Ð
  • portal blood pressure
    ¹®¸Æ¾Ð
  • positive pressure
    ¾ç¾Ð, Á¤¾Ð
  • pressure
    ¾Ð(·Â)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
CBF capillary blood flow; cerebral blood flow; ciliary beat frequency; coronary blood flow; cortical blo...
HBF hand blood flow; hemispheric blood flow; hemoglobinuric bilious fever; hepatic blood flow; hypothala...
SFP screen filtration pressure; simultaneous foveal perception; spinal fluid pressure; stopped flow pres...
EHBF estimated hepatic blood flow; exercise hyperemia blood flow; extrahepatic blood flow
MBF medullary blood flow; muscle blood flow; myocardial blood flow
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
Study 1 study
Study 2 study
Study A study
Study B study
Study I study
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • pressure molding machine

    pressure necrosis

    ¾Ð¹Ú ±«»ç
  • air study
    °ø±â °Ë»ç, °ø±â ÁÖÀÔ °Ë»ç, °ø±â °Ë»ç¹ý, °ø±â ÁÖÀÔ °Ë»ç¹ý
  • arterial blood gas study
    µ¿¸ÆÇ÷ °³½º ºÐ¾Ð ÃøÁ¤
  • case control study
    ȯÀÚ ´ëÁ¶ ¿¬±¸
  • case study
    Áõ·Ê ¿¬±¸
  • coagulation study
    ÀÀ°í °Ë»ç
  • controlled clinical study
    °ü¸®È­ ½ÃÇè, °ü¸®È­ ÀÓ»ó ½ÃÇè, Ãß°èÇÐÀû °ü¸®È­ ½ÃÇè, Ãß°èÇÐÀû °ü¸®È­ ÀÓ»ó ½ÃÇè
  • cross-sectional study
    Ⱦ´Ü ¿¬±¸¹ý, Ⱦ´Ü Á¶»ç¹ý
  • double-blind study
    ÀÌÁß ¸Í°Ë ¿¬±¸
  • electroencephalographic study
    ³úÆÄ °Ë»ç
  • enzyme marker study
    È¿¼Ò Ç¥Áö ¿¬±¸
  • longitudinal study
    ´©³âÀû ¿¬±¸, Á¾Àû ¿¬±¸, Á¾´Ü ¿¬±¸¹ý
  • microbiologic study
    »ý¹°ÇÐÀû °Ë»ç
  • microinjection study
    ¹Ì¼¼ ÁÖ»ç ¿¬±¸
  • mounted study cast
    ºÎÂøµÈ Áø´Ü ¸ðÇü
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
isovolume pressure-flow curve The relationship between transpulmonary pressure and respiratory air flow, expressed as a function of lung volume.
(05 Mar 2000)
analytic study In epidemiology, a study designed to examine associations, commonly putative or hypothesised causal relationships; usually concerned with identifying or measuring the effects of risk factors or with the health effects of specific exposures.
(05 Mar 2000)
blinded study Clinical trials of drugs are often done blinded so that the patient does not know (is blinded as to) whether they are receiving the product being tested or the control/placebo to ensure that the results of a study are not affected by a possible placebo effect (by the power of suggestion).
(12 Dec 1998)
blind study A study in which the experimenter is unaware of which group is subject to which procedure.
(05 Mar 2000)
case-control study <epidemiology> A study in which the risk factors of people with a disease are compared with those without a disease.
It is an epidemiological method that begins by identifying persons with the disease or condition of interest (the cases) and compares their past history of exposure to identified or suspected risk factors with the past history of similar exposures among persons who resemble the cases but do not have the disease or condition of interest (the controls).
The relationship of an attribute to the disease can therefore be examined by comparing affected and non-affected individuals with regard to the frequency or levels of the attribute in each group.
(05 May 2002)
retrospective study <epidemiology> A study in which people are enrolled and then have their history of risks, infections or disease measured.
(05 Dec 1998)
rosenzweig picture-frustration study A projective test depicting cartoon-like characters in frustrating situations. The scoring of the subject's responses indicates the direction of hostility or aggression, that is, whether he blames himself, the other person, or the set of circumstances.
(12 Dec 1998)
cohort study A study using epidemiological methods, such as a clinical trial, in which a cohort with a particular attribute (e.g., smokers, recipients of a drug) is followed prospectively and compared for some outcome (e.g., disease, cure) with another cohort not possessing the attribute.
(05 Mar 2000)
pioped study <radiology> 251 patients with documented PE on pulmonary angiograms were given V/Q scans: 102 high probability, 105 intermediate probability, 39 low probability, 5 normal or near-normal
(12 Dec 1998)
multicenter study A controlled study executed by several cooperating institutions.
(12 Dec 1998)
multigeneration study Toxicity test in which at least 3 generations of the test organisms are exposed to the substance being assessed. Exposure is usually continuous.
Any medical study which follows a family of people through several generations.
(09 Oct 1997)
crossover study <statistics> A study that compares two or more treatments or interventions in which the subjects or patients, upon completion of the course of one treatment, are switched to another. Usually refers to a study in which the subject is switched from the experimental to the control procedure (or vice versa).
In the case of two treatments, a and b, half the subjects are randomly allocated to receive these in the order a, b and half to receive them in the order b, a.
A criticism of this design is that effects of the first treatment may carry over into the period when the second is given.
With this type of study, every patient serves as his or her own control.
(21 Jun 2000)
cross-sectional study <epidemiology> A study in which the presence or absence of disease or other health-related variables are determined in each member of the study population or in a representative sample at one particular time. This contrasts with longitudinal studies which are followed over a period of time.
Synonym: horizontal study.
(18 Jul 2002)
preclinical study A study to test a drug, procedure or other medical treatment in animals. The aim is to collect data in support of safety. Preclinical studies are required before clinical trials can be started.
(12 Dec 1998)
prospective study <epidemiology> A study in which people are initially enrolled and then followed up at subsequent times.
(05 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • flow
    ¹ü¶÷ÇÏ´Ù
  • cash flow
    ij½ÃÇ÷Î(°¨°¡ »ó°¢ºñ¸¦ °¡»êÇÑ ¼øÀÌÀÍ);Çö±Ý À¯ÃâÀÔ;Çö±Ý ÀÚ±Ý
  • energy flow
    (»ýŰèÀÇ)¿¡³ÊÁö È帧
  • flow
    ¸Ó¸®Ä®ÀÌ ´Ã¾îÁö´Ù;(¹Ù¶÷¿¡)¾µ¸®´Ù;(Á¶¼ö°¡)¹Ð´Ù;¸¹ÀÌÀÖ´Ù;È帣°ÔÇÏ´Ù;¹ü¶÷½ÃŰ´Ù;È帧;À¯Ãâ·®;¹Ð¹°;È帣´Ù
  • flow diagram
    ÄÄÇ»ÅÍ ¹®Á¦Ã³¸®¸¦ À§ÇÑ ¼øÀ§Ç¥
  • flow line
    À¯¹®(È­¼º¾Ï À¯µ¿ ¶§¿¡ »ý±â´Â ÁÙ¹«´Ì)
  • flow sheet
    =FLOW DIAGRZM
  • study
    °øºÎ,¼­Àç,Çаú,¹è¿ì´Ù,¿¬±¸ÇÏ´Ù
  • brown study
    ¸ÛÇÏ´Ï»ý°¢¿¡Àá±è
  • case study
    »ç·Ê¿¬±¸;ÄÉÀ̽º ½ºÅ͵ð M
  • desk study
    (¿µ)Ź»ó ¿¬±¸
  • feasibility study
    Ÿ´ç¼º Á¶»ç;¿¹ºñ Á¶»ç
  • field study
    =FIELDWORK
  • home study
    (Åë½Å ±³À°¿¡¼­ÀÇ)ÀÚÅà ÇнÀ;(¹Ì)(¾çºÎ¸ð·Î¼­ÀÇ ÀûºÎ¸¦ ¾Ë¾Æº¸´Â)°¡Á¤Á¶»ç
  • home study
    Åë½Å±³À°
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á